Research paperMONOOLEIN (cas 111-03-5)-based nanoparticles for drug delivery to the central nervous system: A platform for lysosomal storage disorder treatment
-
Add time:08/23/2019 Source:sciencedirect.com
Lysosomal Storage Disorders (LSDs) are characterized by an abnormal accumulation of substrates within the lysosome and comprise more than 50 genetic disorders with a frequency of 1:5000 live births. Nanotechnology may be a promising way to circumvent the drawbacks of the current therapies for lysosomal diseases. The blood circulation time and bioavailability of the enzymes or drugs could be improved by inserting them in nanocarriers, which could decrease and/or avoid the need of frequent intravenous infusions along with the minimization or elimination of associated immunogenic responses. Considering the exposed, we aimed to build monoolein-based nanoparticles stabilized by polysorbate 80 as a smart platform able to reach the central nervous system (CNS) to deliver drugs or enzymes inside lysosomes. We developed and characterized the nanoparticles by dynamic light scattering (DLS), small-angle X-ray scattering (SAXS) and cryogenic transmission electron microscopy (Cryo-TEM). The nanoparticles showed a diameter of 115 nm, which is compatible with in vivo application. The SAXS patterns of the formulations displayed a single broad correlation peak that was fitted to the Teubner-Strey model confirming that disordered bicontinuous structures were obtained. Cryo-TEM images corroborated this finding and showed nanoparticles with size values that are similar to those determined by DLS. Furthermore, the nanoparticles did not present cytotoxicity when they were incubated with human fibroblasts, and demonstrated hemolytic activity proportional to the negative control, proving to be safe for parenteral administration. Through the use of a fluorescent dye to track the nanoparticles inside the cell, we demonstrated that they reached lysosomes after 1 h of treatment. More interestingly, the fluorescent dye was detected in the CNS of mice just after 3 h of treatment. The nanoparticles show great potential to improve the treatment of LSDs with brain impairment, acting as a smart platform to targeted delivery of drugs or enzymes.
We also recommend Trading Suppliers and Manufacturers of MONOOLEIN (cas 111-03-5). Pls Click Website Link as below: cas 111-03-5 suppliers
Prev:An improved method for the synthesis of 1-MONOOLEIN (cas 111-03-5)
Next:MONOOLEIN (cas 111-03-5) cubic phase containing poly(hydroxyethyl acrylate-co-propyl methacrylate-co-methacrylic acid) and its electric field-driven release property) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Effective and highly selective lipase-mediated synthesis of 2-MONOOLEIN (cas 111-03-5) and 1,2-diolein in a two-phase system08/28/2019
- Curcumin containing MONOOLEIN (cas 111-03-5) aqueous dispersions: A preformulative study08/27/2019
- MONOOLEIN (cas 111-03-5) production by triglycerides hydrolysis using immobilized Rhizopus oryzae lipase08/26/2019
- In vitro anti-inflammatory efficacy of Bambusae Caulis in Taeniam extract loaded in MONOOLEIN (cas 111-03-5) cubosomes08/25/2019
- MONOOLEIN (cas 111-03-5) cubic phase containing poly(hydroxyethyl acrylate-co-propyl methacrylate-co-methacrylic acid) and its electric field-driven release property08/24/2019
- An improved method for the synthesis of 1-MONOOLEIN (cas 111-03-5)08/22/2019
- MONOOLEIN (cas 111-03-5)-alginate beads as a platform to promote adenosine cutaneous localization and wound healing08/21/2019
- MONOOLEIN (cas 111-03-5) liquid crystalline phases for topical delivery of crocetin08/20/2019